Accéder au contenu
Merck
Toutes les photos(2)

Principaux documents

Voir toute la documentation

S5567

Sigma-Aldrich

SP600125

≥98% (HPLC), powder or solid, JNK inhibitor

Synonyme(s) :

1,9-Pyrazoloanthrone, Anthrapyrazolone

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(2)

About This Item

Formule empirique (notation de Hill):
C14H8N2O
Numéro CAS:
129-56-6
Poids moléculaire :
220.23
Numéro CE :
204-955-6
Numéro MDL:
MFCD00022289
Code UNSPSC :
12352200
ID de substance PubChem :
24278395
Nomenclature NACRES :
NA.77

Nom du produit

SP600125, ≥98% (HPLC)

Niveau de qualité

200

Essai

≥98% (HPLC)

Couleur

yellow

Solubilité

DMSO: 20 mg/ml, clear to very slightly hazy, faintly yellow to yellow
H2O: insoluble

Température de stockage

2-8°C

Chaîne SMILES 

O=C1c2ccccc2-c3n[nH]c4cccc1c34

InChI

1S/C14H8N2O/c17-14-9-5-2-1-4-8(9)13-12-10(14)6-3-7-11(12)15-16-13/h1-7H,(H,15,16)

Clé InChI

ACPOUJIDANTYHO-UHFFFAOYSA-N

Informations sur le gène

human ... JUN(3725) , MAPK10(5602) , MAPK9(5601)

Application

C2C12 myoblasts were treated with SP600125 to test the stimulation of myogenesis.11 It was used to treat HepG2 cells to test the effects on oxysterol-induced necrosis.12

Actions biochimiques/physiologiques

A novel and selective inhibitor of c-Jun N-terminal kinase (JNK)
SP600125 is an anthrapyrazolone inhibitor of JNK that competes with ATP to inhibit the phosphorylation of c-Jun. It prevents the activation of inflammatory genes such as COX-2, IL-2 IFN-γ and TNF-α.8,9 It prevents the activation of JNK after brain ischemia and may be effective in treatment of ischemic stroke.10

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Équipement de protection individuelle

dust mask type N95 (US), Eyeshields, Gloves

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number
0000330246
0000330246
0000260568
0000260568
SLCL0779

Vous ne trouvez pas la bonne version ?

Si vous avez besoin d'une version particulière, vous pouvez rechercher un certificat spécifique par le numéro de lot.

Rechercher un(e) COA

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Chenglu Peng et al.
Journal of agricultural and food chemistry, 67(32), 9009-9021 (2019-07-19)
Soybean allergy is a serious health risk to humans and animals; β-conglycinin is the primary antigenic protein in soybean. Intestinal porcine epithelial (IPEC-J2) cells were used as an in vitro physiological model of the intestinal epithelium to study the effects
Cheng Yin et al.
Cell transplantation, 28(6), 691-703 (2018-10-24)
Following central nervous system injury in mammals, failed axonal regeneration is closely related to dysneuria. Previous studies have shown that the obvious effects of apolipoprotein E (ApoE) on traumatic brain injury (TBI) were associated with an axonal mechanism. However, little
Adrian Vallejo et al.
Nature communications, 8, 14294-14294 (2017-02-22)
KRAS mutated tumours represent a large fraction of human cancers, but the vast majority remains refractory to current clinical therapies. Thus, a deeper understanding of the molecular mechanisms triggered by KRAS oncogene may yield alternative therapeutic strategies. Here we report
Donia Mili et al.
Molecular cytogenetics, 9, 86-86 (2016-12-08)
The JNK inhibitor SP600125 strongly inhibits cell proliferation in many human cancer cells by blocking mitosis progression and inducing cell death. Despite, all this study, the mechanism by which SP600125 inhibits mitosis-related effects in human cervical cells (HeLa cells) remains
Wen Yuan Luo et al.
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 16(3), 761-783 (2019-05-11)
Targeting mGluR5 has been an attractive strategy to modulate glutamate excitotoxicity for neuroprotection. Although human clinical trials using mGluR5 negative allosteric modulators (NAMs) have included some disappointments, recent investigations have added several more attractive small molecules to this field, providing
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique